2 unknown, 1 suspended. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Suspended 1 |
Follow S-1226: new trials by email Literature Review of S-1226 trials Research Report on S-1226
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia S-1226 - Covid19, SARS-CoV-2 Infection | Phase 2 | Suspended | SolAeroMed Inc. | 30 | 2021-09-15 | 2021-08-23 |
| Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. S-1226 (8%), Placebo - Post Acute COVID-19 Syndrome, Long COVID | Phase 2 | Unknown | SolAeroMed Inc. | 48 | 2021-09-01 | 2021-08-23 |
| Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis S-1226 - Cystic Fibrosis, Bronchiectasis | Phase 2 | Unknown | SolAeroMed Inc. | 12 | 2019-08-08 | 2021-06-16 |
Asthma (1) · Bronchiectasis (1) · COVID-19 (1) · Cystic Fibrosis (1) · Post-Acute COVID-19 Syndrome (1)
SolAeroMed Inc. (3)
Canada (2)